#1 Clinical Trials Search in Europe

Methylphenidate Hydrochloride

This article examines the use of Methylphenidate Hydrochloride, a medication commonly used to treat Attention Deficit Hyperactivity Disorder (ADHD), in various clinical trials. These studies aim to evaluate the drug’s effectiveness, safety, and optimal dosing strategies for different patient populations, including children with autism and adults with childhood-onset ADHD. The trials explore different formulations of methylphenidate, such as extended-release versions, to improve treatment outcomes and patient compliance.

Table of Contents

What is Methylphenidate Hydrochloride?

Methylphenidate Hydrochloride is a medication primarily used to treat attention deficit hyperactivity disorder (ADHD) and, in some cases, narcolepsy. It belongs to a class of drugs known as stimulants[1]. This medication works by altering certain chemicals in the brain, specifically dopamine and norepinephrine, which are involved in attention and behavior control.

Methylphenidate is available under various brand names, including Ritalin, Concerta, and Quillivant XR[2]. These different formulations may have slightly different properties, but they all contain the active ingredient methylphenidate hydrochloride.

What Conditions Does Methylphenidate Treat?

Methylphenidate is primarily used to treat the following conditions:

  • Attention Deficit Hyperactivity Disorder (ADHD): This is the most common use of methylphenidate. It helps improve attention, focus, and reduce hyperactivity and impulsiveness in both children and adults with ADHD[1].
  • Binge Eating Disorder: Some studies have explored the use of methylphenidate in treating binge eating disorder in adults, particularly in those who are overweight or obese[3].
  • Narcolepsy: Although less common, methylphenidate may sometimes be prescribed to treat narcolepsy, a sleep disorder characterized by excessive daytime sleepiness.

Different Formulations of Methylphenidate

Methylphenidate comes in various formulations, each designed to provide different release patterns and durations of effect:

  • Immediate Release (IR): These formulations release the medication quickly and typically need to be taken multiple times a day.
  • Extended Release (ER or XR): These formulations release the medication slowly over time, allowing for once-daily dosing. Examples include:
    • OROS Methylphenidate (Concerta): This formulation uses a special technology to release the medication in an increasing pattern throughout the day[4].
    • SODAS Methylphenidate (Ritalin LA): This formulation uses beads to provide two releases of medication throughout the day[4].
    • Quillivant XR: This is a liquid, extended-release formulation of methylphenidate[2].

Dosage and Administration

The dosage of methylphenidate varies depending on the specific formulation, the condition being treated, and individual patient factors. Here are some general guidelines:

  • For ADHD in adults: Doses may range from 18 mg to 72 mg per day for extended-release formulations[1].
  • For ADHD in children: Dosing is typically started low and gradually increased. For example, Quillivant XR might be started at 20 mg per day and increased up to 60 mg per day[2].
  • For binge eating disorder: Studies have explored doses ranging from 18 mg to 72 mg per day[3].

It’s crucial to follow your doctor’s instructions precisely when taking methylphenidate. Never adjust your dose without consulting your healthcare provider.

Effectiveness of Methylphenidate

Methylphenidate has been shown to be effective in treating ADHD symptoms in both children and adults. Clinical trials have used various measures to assess its effectiveness:

  • ADHD Rating Scale (ADHD-RS): This scale measures the severity of ADHD symptoms. Lower scores indicate improvement in symptoms[1].
  • Clinical Global Impression (CGI) scales: These scales help clinicians assess overall illness severity and improvement[1].
  • Sheehan Disability Scale (SDS): This scale measures how symptoms impact daily life activities[1].

Studies have shown that methylphenidate can significantly improve these measures compared to placebo, indicating its effectiveness in managing ADHD symptoms.

Potential Side Effects

Like all medications, methylphenidate can cause side effects. Common side effects may include:

  • Decreased appetite
  • Trouble sleeping
  • Headache
  • Stomach pain
  • Increased heart rate or blood pressure

It’s important to note that children with autism spectrum disorder (ASD) may be more sensitive to the side effects of methylphenidate, especially at higher doses[2]. Always report any side effects to your healthcare provider.

Use in Special Populations

Methylphenidate has been studied in various populations:

  • Adults with childhood-onset ADHD: Studies have shown that methylphenidate can be effective in adults who have had ADHD since childhood[1].
  • Children with ADHD and Autism Spectrum Disorder (ASD): Research has explored the use of methylphenidate in children who have both ADHD and ASD, using lower doses due to potential increased sensitivity to side effects[2].
  • Healthy adults: Some studies have investigated the effects of methylphenidate on cognitive function in healthy adults without ADHD[5].

It’s important to note that the use of methylphenidate in populations without ADHD, such as for cognitive enhancement in healthy individuals, is not an approved use and carries potential risks.

Study Focus Medication Population Duration Key Outcomes Measured
Dose response in ADHD and autism Quillivant XR (liquid methylphenidate) Children with ADHD and Autism Spectrum Disorder 6 weeks ADHD symptoms, functional outcomes, safety
Efficacy and safety in adults Ritalin LA (extended-release methylphenidate) Adults with childhood-onset ADHD 40 weeks ADHD symptoms, functional impairment, treatment failure rates
Comparison of extended-release formulations OROS MPH (Concerta) vs SODAS MPH (Ritalin LA) Healthy adults Single dose study Pharmacokinetics, subjective effects (likeability)
Efficacy and learning skills OROS Methylphenidate HCl (Concerta) Korean adolescents with ADHD 12 weeks ADHD symptoms, learning skills, cognitive function

FAQ

  • What is Methylphenidate Hydrochloride used for? Methylphenidate Hydrochloride is primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD) in both children and adults. It helps improve focus, attention, and control of impulsive behaviors.
  • Are there different formulations of Methylphenidate Hydrochloride? Yes, there are several formulations, including immediate-release and extended-release versions. Some brand names mentioned in the trials are Quillivant XR, Concerta (OROS methylphenidate), and Ritalin LA.
  • How is the effectiveness of Methylphenidate Hydrochloride measured in clinical trials? Effectiveness is measured using various scales and tests, such as the ADHD Rating Scale, Clinical Global Impression scales, and specific cognitive tests that assess attention, memory, and executive function.
  • Are there any special considerations for using Methylphenidate Hydrochloride in children with autism? Yes, one trial specifically looked at children with both ADHD and Autism Spectrum Disorder (ASD). These children may be more sensitive to the medication's side effects, so the study used lower doses and a gradual dose escalation schedule.
  • How long do these clinical trials typically last? The duration of trials varies. Some last for a few weeks, while others can go up to 40 weeks or longer. This allows researchers to assess both short-term efficacy and long-term safety and effectiveness of the medication.

Ongoing Clinical Trials on Methylphenidate Hydrochloride

  • Study on the Effects of Methylphenidate on Brain Function in Adults with ADHD, with or without Mood Disorders, Compared to Placebo

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on How Methylphenidate Works in Adults with ADHD, Comparing Those with and Without Obesity

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on Lisdexamfetamine and Methylphenidate for Children with ADHD and Type 1 Diabetes

    Recruiting

    1 1 1
    Investigated drugs:
    Poland

  • Study on the Effectiveness of Methylphenidate for Children and Adolescents with KBG Syndrome

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study to evaluate the effect of methylphenidate hydrochloride on the time to wake up in patients in a coma due to acute brain injury

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Denmark France Germany

  • Study on How Reboxetine and Methylphenidate Affect Fatigue in Healthy Individuals

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium

Glossary

  • ADHD: Attention Deficit Hyperactivity Disorder, a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity.
  • Methylphenidate Hydrochloride: A stimulant medication used to treat ADHD by improving attention and reducing hyperactivity and impulsiveness.
  • Extended-release: A formulation of medication designed to release the active ingredient slowly over time, allowing for less frequent dosing.
  • OROS: Osmotic Release Oral System, a technology used in some extended-release formulations of methylphenidate to control drug release over time.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a medication against no treatment.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual medication or placebo.
  • Crossover study: A type of clinical trial where participants receive different treatments in a specific order, allowing comparison of effects within the same individual.
  • Titration: The process of gradually adjusting the dose of a medication to find the optimal balance between effectiveness and side effects.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • CGI-S and CGI-I: Clinical Global Impression – Severity and Improvement scales, used to assess the overall severity of a condition and its improvement with treatment.

References

  1. https://clinicaltrials.gov/study/NCT01259492
  2. https://clinicaltrials.gov/study/NCT02255565
  3. https://clinicaltrials.gov/study/NCT01921582
  4. https://clinicaltrials.gov/study/NCT00302354
  5. https://clinicaltrials.gov/study/NCT00815841